| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
856,317 |
| 52
Week Range: |
$206.39 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
19,405 |
420,533 |
| Total Sell Value |
$0 |
$0 |
$4,136,219 |
$77,127,618 |
| Total People Sold |
0 |
0 |
2 |
8 |
| Total Sell Transactions |
0 |
0 |
2 |
58 |
| End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Baker Brothers Life Sciences Lp |
Director |
– • • |
2015-11-09 |
4 |
B |
$43.00 |
$22,200,588 |
I/I |
507,300 |
33,090,094 |
2.25 |
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2015-11-06 |
4 |
B |
$41.31 |
$17,529,497 |
I/I |
417,924 |
32,582,794 |
2.25 |
- |
|
| Dobmeier Eric |
Chief Operating Officer |
• – – |
2015-11-06 |
4 |
S |
$42.50 |
$741,710 |
D/D |
(17,452) |
80,888 |
|
- |
|
| Gryska David W |
Director |
– • – |
2015-11-05 |
4 |
S |
$43.57 |
$435,737 |
D/D |
(10,000) |
23,950 |
|
- |
|
| Dobmeier Eric |
Chief Operating Officer |
• – – |
2015-11-04 |
5 |
GD |
$0.00 |
$0 |
D/D |
8,223 |
90,117 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2015-11-04 |
4 |
AS |
$43.14 |
$160,395 |
D/D |
(3,718) |
643,588 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2015-11-04 |
4 |
OE |
$5.63 |
$20,932 |
D/D |
3,718 |
647,306 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2015-10-28 |
4 |
OE |
$4.45 |
$165,058 |
D/D |
32,265 |
643,588 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2015-10-05 |
4 |
AS |
$41.30 |
$153,541 |
D/D |
(3,718) |
611,323 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2015-10-05 |
4 |
OE |
$5.63 |
$20,932 |
D/D |
3,718 |
615,041 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2015-09-29 |
4 |
OE |
$12.00 |
$199,991 |
D/D |
14,801 |
194,675 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2015-09-15 |
4 |
B |
$46.31 |
$30,237,807 |
I/I |
626,259 |
32,164,870 |
2.25 |
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2015-09-14 |
4 |
B |
$44.68 |
$14,849,199 |
I/I |
320,438 |
31,538,611 |
2.25 |
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2015-09-11 |
4 |
B |
$40.55 |
$174,517,110 |
I/I |
4,212,787 |
31,218,173 |
2.25 |
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2015-09-03 |
4 |
AS |
$40.12 |
$149,166 |
D/D |
(3,718) |
611,323 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2015-09-03 |
4 |
OE |
$5.63 |
$20,932 |
D/D |
3,718 |
615,041 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2015-08-25 |
4 |
A |
$0.00 |
$0 |
D/D |
64,000 |
611,323 |
|
- |
|
| Dobmeier Eric |
Chief Operating Officer |
• – – |
2015-08-25 |
4 |
A |
$0.00 |
$0 |
D/D |
19,000 |
98,340 |
|
- |
|
| Drachman Jonathan G |
CMO & EVP, R & D |
• – – |
2015-08-25 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
82,724 |
|
- |
|
| Cline Darren S |
SVP, Commercial |
• – – |
2015-08-25 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
43,482 |
|
- |
|
| Liu Jean I |
GC/EVP, Leg Affairs |
• – – |
2015-08-25 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
36,400 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2015-08-25 |
4 |
A |
$0.00 |
$0 |
D/D |
17,000 |
179,874 |
|
- |
|
| Himes Vaughn B |
EVP, Proc Svcs & Tech Ops |
• – – |
2015-08-25 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
76,212 |
|
- |
|
| Dobmeier Eric |
Chief Operating Officer |
• – – |
2015-08-24 |
4 |
OE |
$15.46 |
$99,985 |
D/D |
4,933 |
79,340 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2015-08-20 |
4 |
AS |
$42.02 |
$1,334,440 |
D/D |
(31,754) |
525,268 |
|
- |
|
1805 Records found
|
|
Page 34 of 73 |
|
|
